667 Targeting the JAK/STAT pathway for CTCL therapy

Targeting the EGFR pathway for cancer therapy.

Clinical studies have shown that HER-2/Neu is over-expressed in up to one-third of patients with a variety of cancers, including B-cell acute lymphoblastic leukemia (B-ALL), breast cancer and lung cancer, and that these patients are frequently resistant to conventional chemo-therapies. Additionally, in most patients with multiple myeloma, the malignant cells over-express a number of epidermal g...

Targeting the RB-pathway in cancer therapy.

The RB-pathway, consisting of inhibitors and activators of cyclin-dependent kinases, the retinoblastoma tumor suppressor (RB), and the E2F-family of transcription factors, plays critical roles in the regulation of cell cycle progression and cell death. Components of this pathway, particularly p16Ink4a, cyclin D1, and RB, are frequently altered in sporadic human cancers to promote deregulated ce...

Brentuximab vedotin: targeting CD30 as standard in CTCL

Molecular Pathways: Targeting the TGF-b Pathway for Cancer Therapy

TGF-b is a ubiquitous cytokine that plays an active role in many cellular processes. Nearly every cell type has the ability to secrete TGF-b, as well as the ability to respond to TGF-b via the presence of TGF-b receptors on the cell surface. Consequently, gain or loss of function of the TGF-b pathway and its components are known to lead to a variety of diseases, including cancer. In epithelial ...

Molecular pathways: targeting the TGF-β pathway for cancer therapy.

TGF-β is a ubiquitous cytokine that plays an active role in many cellular processes. Nearly every cell type has the ability to secrete TGF-β, as well as the ability to respond to TGF-β via the presence of TGF-β receptors on the cell surface. Consequently, gain or loss of function of the TGF-β pathway and its components are known to lead to a variety of diseases, including cancer. In epithelial ...